Drug Profile

Research programme: isocitrate dehydrogenase inhibitors - Daiichi Sankyo/National Cancer Center

Alternative Names: IDH1 inhibitors - Daiichi Sankya/National Cancer Cantre

Latest Information Update: 30 Dec 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Daiichi Sankyo Company; National Cancer Center (Tokyo)
Class 1 ring heterocyclic compounds; Antibodies; Antineoplastics; Isoxazoles
Mechanism of Action Isocitrate dehydrogenase 1 inhibitors; Isocitrate dehydrogenase 2 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

30 Dec 2022 Discontinued - Preclinical for Cancer in Japan (unspecified route)
28 May 2020 No recent reports of development identified for preclinical development in Cancer in Japan
14 Apr 2016 Preclinical trials in Cancer in Japan (unspecified route)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com